Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Novartis AG (0QLR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
84.47 -0.50    -0.59%
18/04 - Closed. Currency in CHF ( Disclaimer )
  • Volume: 290,071
  • Bid/Ask: 82.36 / 86.58
  • Day's Range: 84.32 - 84.80
Type:  Equity
Market:  United Kingdom
ISIN:  CH0012005267 
SEDOL:  B10S3M3
Novartis 84.47 -0.50 -0.59%

0QLR Ratios

 
Use this page to view Novartis key financial ratios such as their Price-to-Earnings (P/E Ratio), Earnings-Per-Share (EPS), Return-On-Investment (ROI) and others based on the latest NOVN financial reports.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM 23.78 76.03
Price to Sales TTM 4.37 10.36
Price to Cash Flow MRQ 14.09 32.69
Price to Free Cash Flow TTM 15.2 47.78
Price to Book MRQ 4.37 22.81
Price to Tangible Book MRQ 114.62 94.09
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 74.24% 76.39
Gross Margin 5YA 71.65% 74.27
Operating margin TTM 27.09% 32.63
Operating margin 5YA 24.17% 31.25
Pretax margin TTM 19.55% 27.36
Pretax margin 5YA 25.72% 27.31
Net Profit margin TTM 31.83% 22.37
Net Profit margin 5YA 25.32% 23.02
   
Revenue/Share TTM 22.7 1,051.36
Basic EPS ANN 7.15 201.23
Diluted EPS ANN 7.1 201.2
Book Value/Share MRQ 22.7 1,350.81
Tangible Book Value/Share MRQ 0.87 1,007.44
Cash/Share MRQ 6.52 123.8
Cash Flow/Share TTM 7.03 193.46
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM 16.16% 50.69
Return on Equity 5YA 19.17% 52.52
Return on Assets TTM 13.67% 17.7
Return on Assets 5YA 9.92% 19.38
Return on Investment TTM 13.7% 40.35
Return on Investment 5YA 11.69% 40.4
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 0% 9.15
EPS(TTM) vs TTM 1 Yr. Ago TTM 124.25% 9.4
5 Year EPS Growth 5YA 5.63% 26.07
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 0% 16.46
Sales (TTM) vs TTM 1 Yr. Ago TTM 7.36% 18.48
5 Year Sales Growth 5YA 0.24% 12.76
5 Year Capital Spending Growth 5YA -3.31% 14.28
   
Quick Ratio MRQ 0.8 0.96
Current Ratio MRQ 1.16 1.4
LT Debt to Equity MRQ 39.51% 49.98
Total Debt to Equity MRQ 56.65% 61.07
Efficiency    
Asset Turnover TTM 0.43 0.61
Inventory Turnover TTM 1.84 1.65
Revenue/Employee TTM 613.49K 17.30M
Net Income/Employee TTM 195.30K 2.20M
Receivable Turnover TTM 6.56 3.66
   
Dividend Yield ANN 3.94% 1.87
Dividend Yield 5 Year Avg. 5YA 4.28% 2.26
Dividend Growth Rate ANN 6.45% 15.51
Payout Ratio TTM 48.86% 44.42
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVN Price Commentary

Write your thoughts about Novartis AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lee Taylor
Lee Taylor Dec 01, 2021 10:39
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Novartis is trading at a value last seen in 2018; the funds released from a Sandoz divestment need to be directed towards further patient innovation from this Swiss Pharma major …
Lukas Bednall
Lukas Bednall Sep 28, 2021 15:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hi Guys, I have been invested in Novartis for 5 years and have closely followed the pharmaceutical industry for years. I have been very disappointed with the returns and am looking to transfer my portfolio into riskier assets. Upon research, I think I may have found an even better pharmaceutical company going by the name of SpectrumX. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trials for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email